Abstract
Activation of the BRAF kinase is implicated in the oncogenesis of multiple human tumors, particularly thyroid cancer, colorectal cancer and melanoma. BRAF mutations serve as pivotal modulators of the immunomodulatory landscape within tumors, critically shaping host immune responses and modulating efficacy to cancer immunotherapy. Here, we reviewed the impact of BRAF mutations on the composition and function of tumor immune microenvironment and summarized current therapeutic strategies targeting BRAF. Overall, BRAF mutations significantly modulates cancer treatment outcomes through its effects on immune regulation. Targeting BRAF mutations at different stages of tumor initiation and progression may provide valuable insights for the development of innovative clinical interventions.